Exhibitors and other promotional activities

We are grateful to all our sponsors and exhibitors (which includes pharmaceutical companies), whose funding have contributed towards this independently produced meeting and programme. Sponsors and exhibitors have not had any editorial input or control over the agenda, scientific content development or choice of speakers, excluding dedicated industry symposia and masterclasses. 

The exhibition is an integral part of the conference, providing delegates with the opportunity to converse directly with industry experts about development and research in cardiovascular products and innovation.

See a full list of our exhibitors below:

Exhibitors for 2026

ALNYLAM IS LEADING THE RNAi REVOLUTION®

Alnylam is pioneering RNA interference (RNAi) which can silence genes that cause or contribute to disease by disrupting the production of specific proteins. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs, approved medicines and a rapidly expanding and robust pipeline. Today, the Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. Alnylam is headquartered in Cambridge, MA, US, whilst its UK and Ireland headquarters are in Maidenhead, UK.

AstraZeneca is a global, science-led biopharmaceutical company, headquartered in the UK, that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals. For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.  

Stand number: 11

Website: https://www.astrazeneca.co.uk 

Bayer is a life sciences company and a global leader in healthcare and nutrition. Our products and services are designed to support efforts to overcome the major challenges presented by a growing and aging global population.

In the UK, Bayer is committed to supporting and addressing the needs of patients, the NHS and the clinical community through ongoing research and partnerships, working in a wide range of areas to maximise both clinical benefit and value delivered by new treatment approaches.

At Bayer, our mission is “Health for all, Hunger for none”. Through scientific innovations, we endeavour to shape the future of healthcare and nutrition. 

Website: https://pro.bayer.co.uk/

PP-BEY-GB-0241 April 2026

British Heart Foundation (BHF) powers groundbreaking scientific research into cardiovascular disease to save and improve lives. We fund over £100 million of lifesaving research into heart and circulatory diseases each year. We support you when you need us most. And we campaign for a healthier world.

Website: https://www.bhf.org.uk/

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve outcomes and enhance lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow.

Website: www.boehringer-ingelheim.com/uk (UK) or www.boehringer-ingelheim.com/ie (Ireland)

Boehringer Ingelheim has provided funding for BCS 2026 with no input into the conference agenda, speaker selection or presentation content beyond the Boehringer Ingelheim ‘Hot Topic’ session.

NP-GB-107448  May 2026

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. 

Website: bms.com/gb 

The British Inherited Cardiovascular Conditions Society (BICCS), formerly the AICC, is the national body representing healthcare professionals managing patients and their families with a range of genetic diseases, primarily affecting the heart.

These inherited cardiovascular conditions (ICCs) can affect all ages, can be difficult to diagnose, can run in families and can affect quality of life and sometimes be associated with serious complications including sudden death.

BICCS plays a vital role in representing the healthcare community at a national level and is dedicated to bringing healthcare professionals together to meet, learn, educate and collaborate–all with one shared goal: delivering the highest level of care to our patients. If you are involved in managing patients with ICCs–or simply interested in expanding your expertise–we encourage you to become part of the BICCS community.

The BSH are the voice of Heart Failure – a UK wide community of health care professionals . We connect national expertise to improve heart failure. Our focus is on prevention and improving the impact on patients and society. We do this through education, lobbying, raising awareness and supporting research. 

We represent and support echocardiography professionals working at all levels and in all areas of the field. We provide our members with support to deliver the highest standard of care in echocardiography. We are a leading provider of education and accreditation and produce guidelines and resources to promote best practice.

Stand number: 25

Website: https://www.bsecho.org/

Cardiovascular Care Partnership (UK) is a patient-led charity working alongside clinicians to champion the voice of patients and carers in cardiovascular care. We collaborate on research, innovation, and service development to improve outcomes. Together, we can deliver more effective, person-centred cardiovascular services across the UK.

Stand number: 21

Website: https://www.ccpuk.org.uk/

Consent today is not fit for purpose. Even in advanced hospitals, it remains largely paper-based, leading to high medicolegal risk, poor patient understanding, and operational inefficiency. Over 50% of consent is completed on the day of surgery, contributing to delays and cancellations, while errors and omissions are common.

Concentric is the UK’s leading digital consent-to-treatment application, designed to transform how hospitals manage consent, shared decision-making, and medicolegal risk. Used by 40+ NHS Trusts, Concentric supports more than 2 million patients each year.

Clinicians use Concentric to create personalised, evidence-based consent using a library of 3,000+ procedure templates. Consent information is shared securely with patients ahead of treatment, enabling remote and two-stage consent pathways. The platform integrates seamlessly with existing clinical systems and workflows.

Concentric delivers system-wide benefits with an estimated ~50% reduction in medicolegal risk, improved operational efficiency, including fewer delays and cancellations, and enhanced patient understanding and shared decision-making.

Cardiac Risk in the Young (CRY) is a UK charity dedicated to preventing sudden cardiac death in young people through awareness, screening, research and support for affected families. CRY funds lifesaving cardiac screening programmes and specialist research to better understand inherited and acquired heart conditions. Our new AI Screening and Research Project explores how artificial intelligence can support clinicians and researchers by analysing cardiac data more efficiently, with the aim of improving early detection, enhancing research insights and helping to protect more young lives.

Data4NHS maintains one of the largest healthcare related databases in the UK.  Registration is free and only available to NHS professionals with a valid NHS email address.  Register with us to have access to our resources including the Data4NHS national directory, recruitment opportunities, events and courses calendar, surveys and e-bulletin.   

Stand number: 42

Website: https://directory.data4nhs.com/

Dr.Noon CVD is a CE-marked, MHRA-accredited AI screening software using already-available fundus imaging that detects cardiovascular risk by analysing subtle changes in retinal blood vessels, with accuracy comparable to CT imaging.

Developed in collaboration with leading cardiologists and featured by the European Society of Cardiology (2024) and the American Heart Association (2025), it enables early detection of cardiovascular disease, even in patients with no symptoms. Unlike QRISK3 and other similar traditional tools relying on statistical methods, Dr.Noon reveals risk that often go unnoticed through vessel visualisation.

Its insights are backed by over 50 peer-reviewed publications, including The Lancet, JAMIA, and the Journal of Insurance Medicine, where it’s been described as a “game-changer” in preventative screening. 

The Heartfelt device is the future of heart failure telemonitoring. An AI-powered, non-contact solution for home use. No wearables, no effort. It provides 13 days’ advance warning of hospitalisation on average and delivers a 47% reduction in heart failure events.
After a heart failure admission, patients are typically discharged from hospital and, on returning home, are asked to monitor their symptoms, notably their weight, on a daily basis. Many of these patients are not able to keep up with this monitoring regime, and a great number of them end up back in hospital when, with more consistent monitoring, they could have remained comfortably in their homes.

As our device doesn’t require any input from the patients, data can be collected consistently and more accurately than the current routine of patients weighing themselves. For the doctors, this consistent stream of good quality data means patients should be able to live longer, healthier lives, and avoid hospital re-admissions.

The device can be easily installed in the patient’s home and will track the foot volume of the patient over time whenever the patient simply walks past the monitor. As leg oedema (foot swelling) is one of the main symptoms associated with the onset of a heart failure episode, it is one of the key indicators of heart health.

The data is transmitted from the device to the cloud for processing with the aim of flagging-up of significant changes in foot volume, which allows carers and medical professionals to take compensatory action. More often than not, this simply involves ensuring the correct medicines are both prescribed and taken.

For patients, our device brings a level of monitoring previously unavailable and offers the promise of avoiding unnecessary hospital re-admissions.

Heart Research UK is a national charity dedicated to preventing and curing heart diseases.
For 60 years, we have funded high-quality research projects dedicated to finding even better ways to prevent, treat and cure heart diseases. We invest in innovative projects and support the next generation of cardiovascular researchers, accelerating progress toward better outcomes for patients.
We deliver community-based health programmes designed to identify the risk of heart conditions as soon as possible and empower people to take control of their own heart health. Our Healthy Heart Grants empower and support community projects that promote healthier lifestyles and reduce the risk of heart diseases.
We work with respected researchers, healthcare professionals and local communities across the UK to create lasting change for today and the future because everyone deserves the chance of a healthy heart.
 

Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition.

By delivering intelligent CAD analysis and management insights, Heartflow provides physicians with the clarity and confidence that their next clinical decision is the right one for each individual patient.

Heartflow FFRct is the only non-invasive, lesion-specific FFR prospectively validated against invasive gold standards and proven to improve patient outcomes. 

Heartflow has supported clinicians at over 1,800 institutions in managing more than 600,000 patients worldwide.

Heartflow’s vision is to transform CAD from the leading cause of death into a disease that can be managed for life. Our first-of-its-kind AI analysis creates a detailed 3D model of the heart – a window into your patient’s future, empowering you with insights to personalize each treatment journey.

Hi-D Imaging: Precision Starts with Clarity

Hi-D Imaging represents a new standard in structural heart pre-procedural planning. Rather than overwhelming clinicians with raw data, Hi-D Imaging translates complex imaging into intuitive, clinically meaningful visuals, and enhancing confidence in even the most challenging anatomies. The result: faster interpretation, reduced variability, and a clearer path to decision-making.

4TAVR: One CT. One Click. One Report.

4TAVR, the flagship product of Hi-D Imaging, is an AI-powered planning platform that simplifies and standardizes the entire TAVR workflow. With just a single CT upload, the system automatically performs anatomical segmentation, anatomical measurements which leads to optimal valve sizing, evaluates key features with interactive 2D and 3D visuals, and generates a full structured report. Within minutes, clinicians receive a comprehensive and consistent analysis, replacing hours of manual work and reducing variability between operators.

Digital Twin Lab: One Stop Solution for Testing

Structural heart diseases are not just anatomical conditions, they are fundamentally flow-driven disorders. Whether in valve disease, congenital defects, or aortic pathologies, hemodynamics determine disease progression, treatment response, and device performance. Yet today, our ability to predict patient-specific flow remains limited, with most decisions still relying on static imaging and simplified assumptions.

Why does this matter now? Because the field is at a turning point. With the rapid expansion of transcatheter therapies and increasingly complex patient populations, the need to predict outcomes before intervention is becoming critical for improving patient selection, increasing procedural confidence, and de-risking innovation.

This is where Hi-D Imaging’s physically enhanced digital twin technology introduces a new paradigm. Starting from routine CT or MRI data, patient-specific anatomies are translated into high-fidelity models and combined with advanced in-vitro flow measurements. This approach reconstructs four-dimensional hemodynamics, capturing both instantaneous and phase-averaged flow fields. Unlike purely computational approaches, these digital twins are grounded in measured physics, providing validated insights into flow patterns, pressure gradients, vortex formation, and device–flow interactions.

The potential is substantial. For virtual clinical trials, digital twins enable simulation of therapies across diverse patient cohorts, supporting better patient selection, optimized trial design, and increased confidence in outcomes before first-in-human studies. For medtech R&D, they offer realistic and reproducible environments to accelerate design, validate simulations, and reduce uncertainty. Importantly, this approach can also contribute to reducing reliance on animal studies by replicating physiological conditions in a controlled, patient-specific setting.

Holly Health is a pioneering digital health coaching platform exhibiting at the BCS Annual Conference 2026. Grounded in behavioural science and lifestyle medicine, brought to life with user friendly app technology, Holly Health provides a scalable solution for prevention of CVD risk factors.

Around 80% of CVD events are preventable through lifestyle modification. Holly Health Habit Coach supports patients with life outside the clinic, in their home and neighbourhood, by fostering sustainable habits in nutrition, movement, sleep, and mental health.

Services offered:

  • Population health self-management intervention (with CVD focus)
  • Follow on support after Cardiac Rehab
  • Research studies, focused on patients with hypertension

 

Stop by the Holly Health stand at BCS 2026 to see how their personalised “digital health coach” is bridging the gap between medical advice and daily action, turning long-term health goals into manageable, everyday wins.

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases.

MSD has provided funding for BCS 2026 but has had no further input into any other aspect of this conference, aside from an MSD non-promotional medical exhibition stand.

Date of Prep: April 2026 | GB-NON-12937

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

In the UK, we champion health and lives through pioneering NHS partnerships, innovative collaborations and a clear focus on the greatest healthcare challenges we all face. We are where science meets hope.

Website: https://www.novartis.com/uk-en/ 

Novartis Pharmaceuticals UK Ltd. has provided funding only for the BCS 2026 as part of a sponsorship. Novartis has had no input into the content, organisation, conduct or outputs relating to the Event.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.

Stand number 45


Website: https://www.novonordisk.co.uk/

Novo Nordisk has provided funding via sponsorship for BCS 2026, for which we have received stand space and two Novo Nordisk organised symposia sessions. Novo Nordisk has otherwise had no input into the agenda content or any other outputs of this event.

Pfizer Ltd has provided financial support towards the BCS Annual Conference 2026, but have had no input into the meeting agenda, speaker(s) selection and presentation(s), with the exception of the Pfizer Ltd promotional symposium and non-promotional workshops, for which Pfizer Ltd are fully responsible.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products, including innovative medicines and vaccines.

PP-UNP-GBR-14734. May 2026

Pharma Nord is a European manufacturer of evidence-based nutritional supplements and medicinal preparations, with over 30 years’ experience supporting clinical practice. Our focus is on scientifically documented formulations with proven bioavailability, safety and quality.

Pharma Nord products are manufactured under strict Danish pharmaceutical control at our state-of-the-art production facility based in Vojens, Denmark, ensuring consistent products suitable for clinical use and research.

Pharma Nord formulations are widely used in international clinical trials, particularly in cardiovascular health, and are included in a broad range of published scientific research.

Our flagship formulation is ‘Bio-Quinone Q10’, a leading coenzyme Q10 formulation used in over 100 peer-reviewed scientific studies, including the Q-Symbio heart failure trial and the KiSel-10 study investigating cardiovascular outcomes and longevity.

This evidence-led approach makes Pharma Nord a trusted supplier of nutritional preparations for clinicians, researchers and consumers alike.

Website: https://www.pharmanord.co.uk/ 

The Primary Care Cardiovascular Society (PCCS) is a multi-disciplinary society reflecting the ideas and opinions of primary care healthcare professionals throughout the UK involved in managing cardiovascular patient care and improving cardiovascular health.

Our range of conferences throughout the year provide a stimulating forum for hearing the latest advances in cardiovascular medicine, sharing best practice and networking with colleagues and peers. 


Recordati Pharmaceuticals Limited is part of Recordati S.p.A., a global pharmaceutical group with a 100-year heritage, dedicated to delivering value-added medicines that help people unlock the full potential of life. In the UK we focus on the commercialisation and distribution of therapies across key areas such as urology, uro-oncology and cardiovascular health, supporting patients and healthcare professionals through its established primary and specialty care portfolio.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

Website: https://www.sanofi.co.uk/en

Sky Labs helps patients with chronic diseases lead healthy and fulfilling lives without limitations, even beyond the hospital setting.

As an AI healthcare platform company driving global innovation, we aim to prevent disease and shape a healthier future through precise daily monitoring.

In particular, CART’s 24-hr ambulatory blood pressure monitoring (ABPM) technology has received reimbursement approval from the National Health Insurance Service in Korea. It has been adopted by over 1,900 hospitals and clinics and has recorded over 240,000 prescriptions within just 1.5 years of its launch.

Sky Labs will continue to enhance quality of life and contribute to building a healthier and happier society.

Living Life to the Full

Spacelabs Healthcare is solely dedicated to developing patient monitoring and diagnostic cardiology technologies and services that empower providers to deliver exceptional patient care.

Legacy of Innovation. Future of Possibility

We were there. In 1965, our groundbreaking telemetry became the first test of remote monitoring as it tracked the health of astronauts circling the globe. This auspicious beginning set Spacelabs Healthcare on a mission to advance care here on Earth and it led us to the moniker we proudly wear today.

But our name is not simply based on where we’ve been. It’s a reflection of the opportunities before us. We see limitless possibilities to advance patient care. New frontiers to explore. Pioneering advancements to chart.

We are inspired to solve the problems healthcare providers face in their quest to provide exceptional care.

Changing what’s possible for women in cardiology

The British Cardiovascular Society is committed to increasing the number of women training in cardiology and to support women cardiologists already working within the specialty.

We want to champion changes, address gender inequality in working practice and create a community of female cardiology trainees and consultants across the UK. The aims of the BCS Women in Cardiology team are to:

  • Engage – To develop new initiatives to attract female doctors to cardiology in the UK
  • Collaborate – To work with other cardiology societies to identify and address reasons for gender inequality
  • Support – To champion changes in working practice which promote equity for male and female cardiologists and trainees
  • Inform – To provide contemporary educational resources and support re issues relevant to women in cardiology
  • Network – To create a community of female cardiology trainees/consultants across the UK

The UK CARDIO‑IMID Partnership is the first national, interdisciplinary network of rheumatology and cardiovascular clinicians, scientists, and researchers dedicated to addressing the unmet needs of people with immune‑mediated inflammatory diseases (IMIDs) and cardiovascular involvement. Our mission is to transform care for CARDIO-IMID patients through improved understanding of inflammation science, enhanced diagnostics and monitoring, and precision therapeutics.

Established in 2023 with Medical Research Council and British Heart Foundation co‑funding, the Partnership builds on an NIHR‑BHF–supported network spanning 38 centres across all UK nations. It provides a patient‑centred, collaborative infrastructure to support scalable experimental medicine research, targeted therapeutic trials, training, education, and sharing of best practice in cardio‑rheumatology.

The Partnership is inclusive and welcomes collaborators. Our free UK CARDIO‑IMID Hub, hosted on MEDShr, delivers bespoke cardio‑rheumatology education from world‑leading experts to healthcare professionals across the UK and Republic of Ireland.

ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. 

Website: www.zoll.com

Exhibition Hall

Book your stand and symposia

If you haven’t already, it’s time to book your stand and symposia at the UK’s leading and largest cardiovascular event. BCS2025 offers a variety of opportunities to showcase your company, products and initiatives to an audience of over 2,000 healthcare professionals in the field of cardiology.

The conference, returns to Manchester Central and predominantly attracts consultant and trainee cardiologists, but delegates also include nurses, cardiac physiologists, scientists, and primary care staff.

The event attracts high profile speakers from the UK and overseas, including the leadership of the European Society of Cardiology, American College of Cardiology and the Cardiological Society of India, and provides education across the cardiology curriculum to fulfil the needs of trainees and the revalidation requirements of consultants.

Key elements of the conference include the BCS Education Zone, offering tailored, one-to-one, hands-on training for simulator and imaging, masterclasses, moderated posters and the ever popular ‘Hot Topics’ zones. All are situated in the Education Hall alongside our exhibitors providing a constant hub of activity and increased footfall.